Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We present the case of a 28-year-old man with an IDH1 and TP53 mutant high grade glioma with abnormalities in chromosomes 1 and 19 suggestive of anaplastic oligodendroglioma that rapidly progressed to widespread metastatic disease.
|
30738431 |
2019 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
• APT signals were significantly higher in IDH-wild type compared to IDH-mutant high-grade glioma.
|
31175415 |
2019 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PET with <sup>18</sup>F-GE-180 and <sup>18</sup>F-FET provides differing imaging information in HGG dependent on the IDH-mutational status, with diverging spatial overlap and vast exceedance of contrast-enhancement in MRI.
|
30244386 |
2019 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We retrospectively analyzed 47 patients who underwent an advanced-MR study with DTI followed by surgical intervention with a subsequent histologic diagnosis of High-Grade Glioma (HGG) and immunohistochemical evaluation of IDH1 (Isocitrate DeHydrogenase) mutation status.
|
31153561 |
2019 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most IDH-wildtype tumors showing histopathological and radiological features of low-grade diffuse astrocytoma exhibit molecular and clinical features of high-grade glioma and may represent an early stage of primary glioblastoma.
|
29444314 |
2018 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
|
29288860 |
2018 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data support the possibility of a functional tricarboxylic acid cycle that runs in reductive manner, as a probable mechanism of action of bevacizumab in IDH1 mutated gliomas and propose a new target pathway for effective treatment of malignant gliomas.
|
30511933 |
2018 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CMRO<sub>2</sub> showed the highest diagnostic performance for IDH gene mutation detection in low-grade glioma (AUC, 0.818) and MTI in high-grade glioma (AUC, 0.854) and for all WHO grades (AUC, 0.899) among all biomarkers.
|
27982759 |
2017 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
En bloc resection revealed a high-grade glioma with sarcomatous components that was immunoreactive for the R132H variant of IDH1 by antibody.
|
27153165 |
2017 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
|
28122345 |
2017 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
|
26618343 |
2016 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patient 2, with malignant glioma with primitive neuroectodermal tumor (MGPNET), had a secondary GBM with a noncanonical isocitrate dehydrogenase 1 (IDH1) mutation and 11-year-survival; autopsy showed encasement of the entire bilateral ventricular system by SVS.
|
26308254 |
2016 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
|
26618343 |
2016 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with IDH1-WT show reduced NCF compared with those with IDH1-M malignant gliomas.
|
27576872 |
2016 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It is proposed that isocitrate dehydrogenase 1 (IDH1) mutation predicts the outcome in patients with high-grade glioma.
|
26316565 |
2015 |
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Classification based on IDH1/2 mutation status and Ki-67 expression level could be more convenient for clinical application and guide personalized treatment in malignant gliomas.
|
26338964 |
2015 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recent investigations of malignant gliomas have identified additional genetic and chromosomal abnormalities which cluster with IDH1 mutations into two distinct subgroups.
|
25471051 |
2015 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
|
25391653 |
2015 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Mutational landscape and clonal architecture in grade II and III gliomas.
|
25848751 |
2015 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The NRF2 activity is increased in a significant proportion of malignant gliomas in general but decreased in the majority of IDH1/2-mutant anaplastic gliomas.
|
25304134 |
2015 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, mutations of the ATRX gene have been found in various subtypes and grades of gliomas and were shown to refine the prognosis of malignant gliomas in combination with IDH and 1p/19q status.
|
24559763 |
2014 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase 1 gene (IDH1) R132H mutation status was also recently identified as a prognostic factor for malignant gliomas.
|
24929863 |
2014 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identify miR148a as a novel, G-CIMP-associated miRNA whose methylation is tightly correlated with IDH1 mutation and associated with improved survival in patients with malignant glioma.
|
25224277 |
2014 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results of this study suggest that IDH1 mutation may be associated with polySia expression pathways in malignant gliomas.
|
25164322 |
2014 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the expression of Sox11 in 132 diffuse astrocytomas in relation to the regulator cell marker nestin, c-Met and IDH1-R132H, which have shown to be differentially expressed among the molecular subgroups of malignant gliomas, as well as to an inducer of astrocytic differentiation, that is, signal transducer and activator of transcription (p-STAT-3), clinicopathological features and survival.
|
23619925 |
2013 |